Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in Treatment Resistant Bipolar Depression
NCT06506019Phase 1Active, not recruiting
- Sponsor
- University Health Network
- Start
- Oct 2024
- Primary completion
- Sep 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in bipolar disorder (BD), sponsored by University Health Network. Primary endpoints: Correlation of Amygdala Activity on fMRI with MADRS Score at 4 weeks, Change in Depression Symptoms at 4 weeks and 2 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT06506019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06506019.